AYALA PHARMACEUTICALS, INC. — Operating Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/7c92a9d1-8a34-4ecf-ba64-780b9c46d007/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2023 | $-36.3M | 2023-01-01 – 2023-12-31 | evidence 0001493152-24-014822 |
| FY 2022 | $-37.5M | 2022-01-01 – 2022-12-31 | evidence 0001493152-24-014822 |
| FY 2021 | $-18.8M | 2020-11-01 – 2021-10-31 | evidence 0001493152-22-004469 |
| FY 2020 | $-26.4M | 2019-11-01 – 2020-10-31 | evidence 0001493152-21-001656 |
| FY 2019 | $-18.0M | 2018-11-01 – 2019-10-31 | evidence 0001493152-19-019523 |
| FY 2018 | $-70.4M | 2017-11-01 – 2018-10-31 | evidence 0001493152-19-000489 |
| FY 2017 | $-98.4M | 2016-11-01 – 2017-10-31 | evidence 0001493152-19-000489 |
| FY 2016 | $-76.5M | 2015-11-01 – 2016-10-31 | evidence 0001493152-17-000250 |
| FY 2015 | $-48.7M | 2014-11-01 – 2015-10-31 | evidence 0001493152-17-014889 |
| FY 2014 | $-19.5M | 2013-11-01 – 2014-10-31 | evidence 0001493152-15-000050 |
| FY 2013 | $-75.5M | 2002-03-01 – 2014-01-31 | evidence 0001144204-14-016138 |
| FY 2012 | $-62.5M | 2002-03-01 – 2013-04-30 | evidence 0001144204-13-034985 |
| FY 2011 | $-48.9M | 2002-03-01 – 2012-04-30 | evidence 0001144204-12-034931 |
| FY 2010 | $-7.9M | 2009-11-01 – 2010-10-31 | evidence 0001144204-12-004201 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
AYALA PHARMACEUTICALS, INC. — all facts · Revenue · Net Income